Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced it will hold its 2025 R&D Day in Midtown, New York, on Tuesday, October 14, at 8:00 a.m. ET. The event …
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that new findings from its Phase 2a trial of ATI-2138, an investigational oral therapy for moderate-to-severe atopic dermatitis, will be featured …
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that it will participate in two upcoming healthcare conferences in September to highlight corporate updates and its development strategy.
Aclaris Therapeutics to Present at Two Investor Conferences in September Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported a second-quarter net loss of $15.4 million and a year-to-date loss of $30.5 million, as the company continues to invest in advancing …
Aclaris Therapeutics Reports Q2 Loss, Highlights Progress in Immuno-Dermatology Pipeline Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced encouraging top-line results from a Phase 2a trial evaluating ATI-2138, its oral investigational treatment targeting moderate-to-severe atopic dermatitis (AD). The study …
Aclaris Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis Trial Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced the appointment of Roland Kolbeck, Ph.D., as its new Chief Scientific Officer, bringing on board a seasoned leader in immunology and drug …
Aclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific Officer Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its inclusion in the Russell 3000® and Russell 2000® Indexes, which became effective yesterday. This milestone marks a significant step …
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and efficacy of ATI-052, an investigational bispecific anti-TSLP/IL-4R antibody that could …
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 Read MoreWAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis (AD). This randomized, …
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in two healthcare conferences in June:
Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025 Read More